Brain scans reveal how new schizophrenia drug cobenfy works
NCT ID NCT07423546
First seen Feb 27, 2026 · Last updated Jun 22, 2026 · Updated 17 times
Summary
This study will use brain scans (PET/MRI) to see how the drug Cobenfy affects dopamine in the brains of 12 people with schizophrenia. Participants will take one of three doses of Cobenfy for 5 weeks and get a brain scan before and after treatment. The goal is to understand how the drug interacts with brain chemistry, not to test if it improves symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New York State Psychiatric Institute
New York, New York, 10032, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cobenfy (xanomeline and trospium chloride)
What this could lead to
If it works, this could help explain how Cobenfy affects brain chemistry in schizophrenia, pointing toward better treatments.
What could go wrong
This is a very small, early-phase study with only 12 people. It is designed to measure brain activity, not to test if the drug works for symptoms. Results may not apply to everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.